Brokerages expect Theravance Biopharma Inc (NASDAQ:TBPH) to post earnings of ($1.06) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest EPS estimate coming in at ($1.15) and the highest estimate coming in at ($1.01). Theravance Biopharma posted earnings per share of ($1.10) during the same quarter last year, which suggests a positive year-over-year growth rate of 3.6%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Theravance Biopharma will report full year earnings of ($4.34) per share for the current year, with EPS estimates ranging from ($4.65) to ($3.92). For the next year, analysts forecast that the company will report earnings of ($4.01) per share, with EPS estimates ranging from ($4.55) to ($3.28). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.50. The firm had revenue of $26.15 million for the quarter, compared to the consensus estimate of $13.92 million.
Several brokerages have commented on TBPH. BidaskClub lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Friday. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Theravance Biopharma in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $44.25.
NASDAQ TBPH traded up $0.18 during trading on Friday, hitting $17.97. The company had a trading volume of 6,981 shares, compared to its average volume of 203,083. Theravance Biopharma has a one year low of $15.18 and a one year high of $31.26. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -4.50 and a beta of 1.64. The company’s fifty day moving average is $21.01 and its 200-day moving average is $20.21.
Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Theravance Biopharma in the 1st quarter worth $156,000. CWM Advisors LLC bought a new position in shares of Theravance Biopharma in the 2nd quarter worth about $167,000. Wolverine Trading LLC bought a new position in shares of Theravance Biopharma in the 2nd quarter worth about $203,000. DekaBank Deutsche Girozentrale increased its stake in shares of Theravance Biopharma by 64.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 19,200 shares of the biopharmaceutical company’s stock worth $306,000 after acquiring an additional 7,500 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Theravance Biopharma by 117.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 28,969 shares of the biopharmaceutical company’s stock worth $473,000 after acquiring an additional 15,627 shares in the last quarter. Institutional investors and hedge funds own 84.16% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
See Also: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.